Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AL-37807 ophthalmic suspension, 0.1%, AL-37807 Ophthalmic Suspension, 1.0%, AL-37807, 1.0%, AL-37807
AL-37807, 0.1% · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| AL-37807 | EXPERIMENTAL | AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks |
| Timolol | ACTIVE_COMPARATOR | Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks |
| AL-37807 vehicle | PLACEBO_COMPARATOR | AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks |
| AL-37807 Suspension | EXPERIMENTAL | - |
| Xalatan | ACTIVE_COMPARATOR | - |
| Timolol Maleate | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AL-37807 ophthalmic suspension, 0.1% | DRUG | - |
| Timolol gel forming solution, 0.5% | DRUG | - |
| AL-37807 ophthalmic solution vehicle | OTHER | - |
| Latanoprost ophthalmic solution | DRUG | - |
| AL-37807 | DRUG | - |
| AL-37807 Ophthalmic Suspension, 1.0% | DRUG | One drop in the study eye(s) once daily for 28 days |
| Latanoprost, 0.005% (Xalatan) | DRUG | One drop in the study eye(s) once daily for 28 days |
| AL-37807 Vehicle | OTHER | One drop in the study eye(s) once daily for 28 days |
| Timolol Maleate Ophthalmic Gel Forming Solution, 0.5% | DRUG | One drop in the study eye(s) once daily for 28 days |
Inclusion Criteria: * Open-angle glaucoma * Ocular hypertension * Must have been on Xalatan for at least 3 months * VA not worse than 0.60 * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Age related * Other protocol-defined exclusion criteria may apply
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
AL-37807, 0.1% is an investigational ophthalmic small molecule being studied for open-angle glaucoma. It is also being evaluated in ocular hypertension. It is a topical eye drop formulation developed by Alcon Inc. and has been tested in Phase 2 clinical trials in the United States.
AL-37807, 0.1% is developed by Alcon Inc., which trades on the New York Stock Exchange under the ticker ALC. Alcon is an eye care company focused on surgical and vision care products, and AL-37807 is part of its ophthalmology pipeline for glaucoma.
AL-37807, 0.1% is in Phase 2 clinical development. It is an investigational therapy and is not approved by the FDA. Three Phase 2 trials have been completed, and no active trials are currently listed. The program has enrolled a total of 336 participants across those completed studies.
AL-37807, 0.1% has been studied in three completed Phase 2 trials: NCT00620256, an adjunctive study with 129 participants; NCT00372931, with 120 participants; and NCT00287521, with 87 participants. All three were randomized, double-blind, placebo-controlled trials conducted in the United States in adults with open-angle glaucoma or ocular hypertension.
Yes. AL-37807, 0.1% is also known as AL-37807 ophthalmic suspension, 0.1%, and is sometimes referenced as AL-37807 Ophthalmic Suspension, 1.0%, or simply AL-37807. These names refer to the same Alcon investigational compound being studied for open-angle glaucoma and ocular hypertension.